Form 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2020

Commission File Number: 001-36515

 

 

Materialise NV

 

 

Technologielaan 15

3001 Leuven

Belgium

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒                  Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

This Form 6-K is incorporated by reference into the registrant’s Registration Statement on Form F-3 (File No. 333-213649).

 

 

 


Third Quarter 2020 Results

Except as otherwise required by the context, references to “Materialise,” “Company,” “we,” “us” and “our” are to Materialise NV and its subsidiaries.

Third Quarter 2020 Results

Total revenue for the third quarter of 2020 decreased 19.2% to 40,785 kEUR compared to 50,449 kEUR for the third quarter of 2019.

Revenue from our Materialise Software segment decreased 12.7% to 9,478 kEUR for the third quarter of 2020 from 10,860 kEUR for the same quarter last year. Recurring revenue of Materialise Software increased by 15.9%.

Revenue from our Materialise Medical segment increased 10.8% to 17,161 kEUR for the third quarter of 2020 compared to 15,488 kEUR for the same period in 2019. Compared to the third quarter of 2019, revenues from our medical software grew 3.1% and revenues from medical devices and services increased 14.5%.

Revenue from our Materialise Manufacturing segment decreased 41.3% to 14,154 kEUR for the third quarter of 2020 from 24,127 kEUR for the third quarter of 2019.

Gross profit was 23,220 kEUR, or 56.9% of total revenue, for the third quarter of 2020 compared to 29,023 kEUR, or 57.5% of total revenue, for the third quarter of 2019.

Research and development (“R&D”), sales and marketing (“S&M”) and general and administrative (“G&A”) expenses decreased, in the aggregate, 11.9% to 24,176 kEUR for the third quarter of 2020 from 27,439 kEUR for the third quarter of 2019. In the third quarter of 2020, we increased our R&D expenses by 4.2%, while our cost reduction initiatives in S&M and G&A resulted in decreases of 18.7% and 11.7%, respectively, compared to the third quarter of 2019.

Net other operating income was 1,157 kEUR compared to 1,332 kEUR for the third quarter of 2019.

Operating result decreased to 201 kEUR from 2,916 kEUR for the third quarter of 2019.

Net financial result was (1,331) kEUR compared to (966) kEUR for the third quarter of 2019. The share in result of joint venture amounted to 0 kEUR compared to (41) kEUR for the same period in 2019. Subsequent to the end of the third quarter, we agreed to acquire substantially all assets of RS Scan, our joint venture partner in RS Print, and thereby acquire the remaining 50% interest in RS Print.

The third quarter of 2020 contained income tax income of 764 kEUR, compared to an income tax expense of (908) kEUR in the third quarter of 2019.

As a result of the above, net loss for the third quarter of 2020 was (366) kEUR, compared to 1,001 kEUR for the same period in 2019. Total comprehensive loss for the third quarter of , which includes exchange differences on translation of foreign operations, was (1,744) kEUR compared to 1,067 kEUR for the 2019 period.

Adjusted EBITDA decreased to 6,023 kEUR from 8,022 kEUR. The Adjusted EBITDA margin (Adjusted EBITDA divided by total revenue) for the third quarter of 2020 was 14.8% compared to 15.9% for the third quarter of 2019.

Segment EBITDA decreased to 3,114 kEUR from 3,769 kEUR while the segment EBITDA margin (segment EBITDA divided by segment revenue) was 32.9% compared to 34.7% for the prior-year period.

Segment EBITDA increased to 5,477 kEUR compared to 2,795 kEUR while the segment EBITDA margin was 31.9% compared to 18.0% for the third quarter of 2019.

Segment EBITDA decreased to (293) kEUR from 3,862 kEUR while the segment EBITDA margin was (2.1)% compared to 16.0% for the third quarter of 2019.

At September 30, 2020, we had cash and equivalents of 110,691 kEUR compared to 128,897 kEUR at December 31, 2019. Gross debt amounted to 117,884 kEUR at September 30, 2020, compared to 127,939 kEUR at December 31, 2019. As a result, our net cash position decreased 8,151 kEUR during the first three quarters of 2020.


Cash flow from operating activities during the first three quarters of 2020 was 14,752 kEUR compared to 22,737 kEUR for the same period in 2019. Total capital expenditures for the third quarter of 2020 were funded with cash flow from operations and available cash, and amounted to 7,536 kEUR. This amount included capital expenditures of 1,846 kEUR related to our internal digital transformation program.

Net shareholders’ equity at September 30, 2020 was 131,399 kEUR compared to 142,675 kEUR at December 31, 2019.

Non-IFRS Measures

Materialise uses EBITDA and Adjusted EBITDA as supplemental financial measures of its financial performance. EBITDA is calculated as net profit plus income taxes, financial expenses (less financial income), shares of loss in a joint venture and depreciation and amortization. Adjusted EBITDA is determined by adding share-based compensation expenses and acquisition-related expenses of business combinations to EBITDA. Management believes these non-IFRS measures to be important measures as they exclude the effects of items which primarily reflect the impact of long-term investment and financing decisions, rather than the performance of the Company’s day-to-day operations. As compared to net profit, these measures are limited in that they do not reflect the periodic costs of certain capitalized tangible and intangible assets used in generating revenues in the Company’s business, or the charges associated with impairments. Management evaluates such items through other financial measures such as capital expenditures and cash flow provided by operating activities. The Company believes that these measurements are useful to measure a company’s ability to grow or as a valuation measurement. The Company’s calculation of EBITDA and Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. EBITDA and Adjusted EBITDA should not be considered as alternatives to net profit or any other performance measure derived in accordance with IFRS. The Company’s presentation of EBITDA and Adjusted EBITDA should not be construed to imply that its future results will be unaffected by unusual or non-recurring items.

Exchange Rate

This document contains translations of certain euro amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from euros to U.S. dollars in this document were made at a rate of EUR 1.00 to USD 1.1708, the reference rate of the European Central Bank on September 30, 2020.

About Materialise

Materialise incorporates 30 years of 3D printing experience into a range of software solutions and 3D printing services, which form the backbone of the 3D printing industry. Materialise’s open and flexible solutions enable players in a wide variety of industries, including healthcare, automotive, aerospace, art and design, and consumer goods, to build innovative 3D printing applications that aim to make the world a better and healthier place. Headquartered in Belgium, with branches worldwide, Materialise combines the largest groups of software developers in the industry with one of the largest and most complete 3D printing facilities in the world.


 

Consolidated income statements (Unaudited)

 

     For the three months ended
September 30,
    For the nine
months ended
September 30,
 
In 000    2020     2020     2019     2020     2019  
     U.S.$                  

Revenue

     47,751       40,785       50,449       125,148       145,968  

Cost of sales

     (20,566     (17,566     (21,426     (57,310     (64,838

Gross profit

     27,186       23,220       29,023       67,838       81,129  

Gross profit as % of revenue

     56.9     56.9     57.5     54.2     55.6

Research and development expenses

     (6,862     (5,861     (5,626     (18,434     (17,411

Sales and marketing expenses

     (12,896     (11,015     (13,545     (33,700     (38,797

General and administrative expenses

     (8,547     (7,300     (8,269     (21,100     (24,453

Net other operating income (expenses)

     1,355       1,157       1,332       2,733       3,959  

Operating (loss) profit

     235       201       2,916       (2,663     4,427  

Financial expenses

     (2,883     (2,462     (1,138     (4,923     (2,647

Financial income

     1.324       1,131       172       1,976       900  

Share in loss of joint venture

     —         —         (41     (39     (245

(Loss) profit before taxes

     (1,323     (1,130     1,909       (5,649     2,434  

Income taxes

     894       764       (908     497       (2,037

Net (loss) profit for the period

     (429     (366     1,001       (5,152     397  

Net (loss) profit attributable to:

          

The owners of the parent

     (359     (307     929       (4,989     325  

Non-controlling interest

     (69     (59     72       (163     72  

Earnings per share attributable to owners of the parent

 

       

Basic

     (0.01     (0.01     0.02       (0.01     0.01  

Diluted

     (0.01     (0.01     0.02       (0.01     0.01  

Weighted average basic shares outstanding

     53,194       53,194       52,891       53,194       52,891  

Weighted average diluted shares outstanding

     53,194       53,194       52,970       53,194       52,930  


 

Consolidated statements of comprehensive income (Unaudited)

 

     For the three months ended
September 30,
    For the nine
months ended
September 30,
 
In 000    2020     2020     2019     2020     2019  
     U.S.$                  

Net profit (loss) for the period

     (429     (366     1,001       (5,152     397  

Other comprehensive income

          

Exchange difference on translation of foreign operations

     (1,612     (1,377     67       (8,165     225  

Other comprehensive income (loss), net of taxes

     (1,612     (1,377     67       (8,165     225  

Total comprehensive income (loss) for the year, net of taxes

     (2,042     (1,744     1,067       (13,318     623  

Total comprehensive income (loss) attributable to:

          

The owners of the parent

     (1,754     (1,498     1,077       (11,969     623  

Non-controlling interest

     (288     (246     (10     (1,349     —    


 

Consolidated statement of financial position (Unaudited)

 

     As of
September
30,
     As of
December
31,
 
In 000    2020      2019  
           

Assets

     

Non-current assets

     

Goodwill

     18,653        20,174  

Intangible assets

     28,790        27,395  

Property, plant & equipment

     88,228        90,331  

Right-of-Use assets

     9,473        10,586  

Investments in joint ventures

     —          39  

Deferred tax assets

     875        192  

Other non-current assets

     12,418        9,391  

Total non-current assets

     158,437        158,108  

Current assets

     

Inventories

     10,046        12,696  

Trade receivables

     30,526        40,322  

Other current assets

     11,087        9,271  

Cash and cash equivalents

     110,691        128,897  

Total current assets

     162,350        191,186  

Total assets

     320,787        349,294  


 

 

     As of
September
30,
    As of
December
31,
 
In 000    2020     2019  
          

Equity and liabilities

    

Equity

    

Share capital

     3,068       3,066  

Share premium

     138,391       138,090  

Consolidated reserves

     (5,185     (195

Other comprehensive income

     (6,979     (1.394

Equity attributable to the owners of the parent

     129,295       139,567  

Non-controlling interest

     2,104       3,107  

Total equity

     131,399       142,675  

Non-current liabilities

    

Loans & borrowings

     93,630       104,673  

Lease liabilities

     5,767       6,427  

Deferred tax liabilities

     5,548       5,747  

Deferred income

     5,236       5,031  

Other non-current liabilities

     672       696  

Total non-current liabilities

     110,853       122,575  

Current liabilities

    

Loans & borrowings

     15,106       13,389  

Lease liabilities

     3,381       3,449  

Trade payables

     15,637       18,516  

Tax payables

     1,392       3,363  

Deferred income

     25,379       27,641  

Other current liabilities

     17,640       17,686  

Total current liabilities

     78,535       84,044  

Total equity and liabilities

     320,787       349,294  


 

Consolidated statement of cash flows (Unaudited)

 

     For the nine months ended
September 30,
 
in 000    2020     2019  
          

Operating activities

    

Net (loss) profit for the period

     (5,153     398  

Non-cash and operational adjustments

    

Depreciation of property, plant & equipment

     11,266       10,722  

Amortization of intangible assets

     3,349       3,360  

Share-based payment expense

           258  

Loss (gain) on disposal of property, plant & equipment

     (16     141  

Movement in provisions

           66  

Movement reserve for bad debt

     36       (135

Financial income

     (1.977     (900

Financial expense

     4.922       2,647  

Impact of foreign currencies

     18       (432

Share in loss of a joint venture (equity method)

     39       245  

(Deferred) income taxes

     (836     2,012  

Other

     —         4  

Working capital adjustment & income tax paid

    

Decrease (increase) in trade receivables and other receivables

     6,765       3,593  

Decrease (increase) in inventories

     2,757       8  

Increase (decrease) in trade payables and other payables

     (4,301     2,263  

Income tax paid & interest received

     (2,457     (1,514

Net cash flow from operating activities

     14,752       22,737  


 

 

     For the nine months ended
September 30,
 
in 000    2020     2019  
          

Investing activities

    

Purchase of property, plant & equipment

     (8,196     (10,325

Purchase of intangible assets

     (5,783     (1,588

Proceeds from the sale of property, plant & equipment & intangible assets (net)

     150       (3

Available for sale investments

    

Advances on capital increases

     —         (875

Convertible loan to third party

     (2,428     (2,500

Investments in subsidiary, net of cash acquired

     —         (7,765

Interest received

     —          

Net cash flow used in investing activities

     (16,258     (23,066

Financing activities

    

Proceeds from loans & borrowings

     —         29,000  

Repayment of loans & borrowings

     (8,909     (8,608

Repayment of finance leases

     (2,997     (2,288

Capital increase

     140       —    

Direct attributable expense of capital increase

     —         —    

Interest paid

     (1,626     (1,713

Other financial income (expense)

     (1,034     (451

Net cash flow from (used in) financing activities

     (14,425     15,941  

Net increase of cash & cash equivalents

     (15,931     15,611  

Cash & cash equivalents at beginning of the year

     128,897       115,506  

Exchange rate differences on cash & cash equivalents

     (2,275     162  

Cash & cash equivalents at end of the period

     110,691       131,279  


 

Reconciliation of Net Profit (Loss) to EBITDA and Adjusted EBITDA (Unaudited)

 

     For the three months
ended September 30,
    For the nine months
ended September 30,
 
In 000    2020     2019     2020     2019  
                  

Net profit (loss) for the period

     (366     1,001       (5,152     397  

Income taxes

     (764     908       (497     2,037  

Financial expenses

     2,462       1,138       4,923       2,647  

Financial income

     (1,131     (172     (1,976     (900

Share in loss of joint venture

     —         41       39       245  

Depreciation and amortization

     4,922       4,904       14,616       14,082  

EBITDA

     5,123       7,820       11,952       18,512  

Share-based compensation expense (1)

     900       60       1,057       256  

Acquisition-related expenses of business combinations (2)

     —         140       —         140  

ADJUSTED EBITDA

     6,023       8,022       13,009       18,908  

 

(1)

Share-based compensation expenses represent the cost of equity-settled and cash-settled share-based payments to employees.

(2)

Acquisition-related expenses of business combinations represent expenses incurred in connection with the Engimplan acquisition.


 

Segment P&L (Unaudited)

 

In 000    Materialise
Software
    Materialise
Medical
    Materialise
Manu-
facturing
    Total
segments
    Unallocated
(1)(2)
    Consolidated  
                          

For the three months ended September 30, 2020

            

Revenues

     9,478       17,161       14,154       40,793       22       40,785  

Segment (adj) EBITDA

     3,114       5,477       (293     8,298       (2,275     6,023  

Segment (adj) EBITDA %

     32.9     31.9     (2.1 %)      20.3       14.8

For the three months ended September 30, 2019

            

Revenues

     10,860       15,488       24,127       50,474       (26     50,449  

Segment EBITDA

     3,769       2,795       3,862       10,426       (2,404     8,022  

Segment EBITDA %

     34.7     18.0     16.0     20.7       15.9
In 000    Materialise
Software
    Materialise
Medical
    Materialise
Manu-
facturing
    Total
segments
    Unallocated
(1)(2)
    Consolidated  
                          

For the nine months ended September 30, 2020

            

Revenues

     28,839       44,541       51,746       125,126       22       125,148  

Segment (adj) EBITDA

     9,516       9,072       1,474       20,063       (7,053     13,009  

Segment (adj) EBITDA %

     33.0     20.4     2.8     16.0       10.4

For the nine months ended September 30, 2019

            

Revenues

     29,529       43,600       72,861       145,990       (22     145,968  

Segment (adj) EBITDA

     8,785       7,306       10,393       26,484       (7,576     18,908  

Segment (adj) EBITDA %

     29.8     16.8     14.3     18.1       13.0

 

(1)

Unallocated Revenues consist of occasional one-off sales in our core competencies not allocated to any of our segments.

(2)

Unallocated segment EBITDA consists of corporate research and development, corporate headquarter costs and other operating income (expense), and the added share-based compensation expenses and acquisition-related expenses of business combinations that are included in Adjusted EBITDA.


 

Reconciliation of Net Profit (Loss) to Segment EBITDA (Unaudited)

 

     For the three months
ended September 30,
    For the nine months
ended September 30,
 
In 000    2020     2019     2020     2019  
                  

Net profit (loss) for the period

     (366     1,001       (5,152     397  

Income taxes

     (764     908       (497     2,037  

Financial cost

     2,462       1,138       4,923       2,647  

Financial income

     (1,131     (172     (1,976     (900

Share in loss of joint venture

       41       39       245  

Operating profit

     201       2,916       (2,663     4,427  

Depreciation and amortization

     4,922       4,904       14,616       14,082  

Corporate research and development

     668       497       2,052       1,510  

Corporate headquarter costs

     3,271       2,978       8,360       8,753  

Other operating income (expense)

     (764     (726     (2,303     (1,833

Segment EBITDA

     8,298       10,426       20,063       26,484  


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

MATERIALISE NV
By:  

/s/ Wilfried Vancraen

Name:   Wilfried Vancraen
Title:   Chief Executive Officer

Date: October 29, 2020